Aqp2
-
Official Full Name
aquaporin 2 (collecting duct)
-
Overview
Aquaporin 2 (AQP2) is a water transport protein that forms water channels in kidney tubules and plays a predominant role in controlling organism water homeostasis. Members of the aquaporin family are multiple pass transmembrane proteins that form homotetr -
Synonyms
AQP2; aquaporin 2 (collecting duct); aquaporin-2; AQP-2; aquaporin-CD; ADH water channel; water-channel aquaporin 2; collecting duct water channel protein; water channel protein for renal collecting duct; AQP-CD; WCH-CD; MGC34501;
- Recombinant Proteins
- Protein Pre-coupled Magnetic Beads
- Amblysomus hottentotus (Hottentot golden mole)
- Bos taurus (Bovine)
- Canis lupus familiaris (Dog) (Canis familiaris)
- Chicken
- Dasypus novemcinctus (Nine-banded armadillo)
- Dugong dugon (Dugong) (Trichechus dugon)
- Elephas maximus (Indian elephant)
- Equus caballus (Horse)
- Erinaceus europaeus (Western European hedgehog)
- Homo sapiens (Human)
- Human
- Macroscelides proboscideus (Short-eared elephant shrew)
- Milnesium tardigradum (Water bear) (Tardigrade)
- Mouse
- Mus musculus (Mouse)
- Orycteropus afer (Aardvark)
- Oryctolagus cuniculus (Rabbit)
- Ovis aries (Sheep)
- Procavia capensis habessinica (Abyssinian hyrax)
- Rat
- Rattus norvegicus (Rat)
- Rhesus Macaque
- Talpa europaea (European mole)
- E.coli
- E.coli expression system
- E.Coli or Yeast
- HEK293
- In Vitro Cell Free System
- In vitro E. coli expression system
- Mammalian Cell
- Wheat Germ
- GST
- His
- His (Fc)
- Avi
- His|GST
- N
- Tag
- Free
Species | Cat.# | Product name | Source (Host) | Tag | Protein Length | Price |
---|---|---|---|---|---|---|
Human | AQP2-733H | Recombinant Human AQP2 protein, GST-tagged | Wheat Germ | GST | ||
Human | AQP2-3593H | Recombinant Human AQP2, His-tagged, GST-tagged | E.coli | His/GST | 271 | |
Human | AQP2-1156HF | Recombinant Full Length Human AQP2 Protein, GST-tagged | In Vitro Cell Free System | GST | 271 amino acids | |
Human | AQP2-0591H | Recombinant Human AQP2 Protein (His177-Ala271), N-GST-tagged | E.coli | N-GST | His177-Ala271 | |
Mouse | Aqp2-3597M | Recombinant Mouse Aqp2, His-tagged | E.Coli or Yeast | His | 271 | |
Mouse | AQP2-1821M | Recombinant Mouse AQP2 Protein | Mammalian Cell | His | ||
Mouse | Aqp2-1953M | Recombinant Mouse Aqp2 Full Length Transmembrane protein, His-tagged | In vitro E. coli expression system | His | 1-271aa | |
Mouse | AQP2-648M-B | Recombinant Mouse AQP2 Protein Pre-coupled Magnetic Beads | HEK293 | |||
Mouse | AQP2-648M | Recombinant Mouse AQP2 Protein, His (Fc)-Avi-tagged | HEK293 | His (Fc)-Avi | ||
Rat | AQP2-737R | Recombinant Rat AQP2 Protein | Mammalian Cell | His | ||
Rat | Aqp2-1034R | Recombinant Rat Aqp2 Full Length Transmembrane protein, His-tagged | In vitro E. coli expression system | His | 1-271aa | |
Rat | AQP2-393R | Recombinant Rat AQP2 Protein, His (Fc)-Avi-tagged | HEK293 | His (Fc)-Avi | ||
Rat | AQP2-393R-B | Recombinant Rat AQP2 Protein Pre-coupled Magnetic Beads | HEK293 | |||
Amblysomus hottentotus (Hottentot golden mole) | RFL-2502AF | Recombinant Full Length Amblysomus Hottentotus Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-109) | |
Bos taurus (Bovine) | RFL-7536BF | Recombinant Full Length Bovine Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-271) | |
Canis lupus familiaris (Dog) (Canis familiaris) | RFL-8058CF | Recombinant Full Length Dog Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-109) | |
Dasypus novemcinctus (Nine-banded armadillo) | RFL-21776DF | Recombinant Full Length Dasypus Novemcinctus Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-109) | |
Dugong dugon (Dugong) (Trichechus dugon) | RFL-34090DF | Recombinant Full Length Dugong Dugon Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-109) | |
Elephas maximus (Indian elephant) | RFL-25798EF | Recombinant Full Length Elephas Maximus Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-109) | |
Equus caballus (Horse) | RFL-17681EF | Recombinant Full Length Horse Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-109) | |
Erinaceus europaeus (Western European hedgehog) | RFL-17138EF | Recombinant Full Length Erinaceus Europaeus Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-109) | |
Homo sapiens (Human) | RFL-15495HF | Recombinant Full Length Human Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-271) | |
Macroscelides proboscideus (Short-eared elephant shrew) | RFL-13721MF | Recombinant Full Length Macroscelides Proboscideus Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-111) | |
Milnesium tardigradum (Water bear) (Tardigrade) | RFL4584MF | Recombinant Full Length Milnesium Tardigradum Aquaporin-2(Aqp2) Protein, Tag-Free | E.coli expression system | Tag-Free | Full Length (1-323) | |
Mus musculus (Mouse) | RFL-31784MF | Recombinant Full Length Mouse Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-271) | |
Orycteropus afer (Aardvark) | RFL-2233OF | Recombinant Full Length Orycteropus Afer Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-109) | |
Oryctolagus cuniculus (Rabbit) | RFL-16287OF | Recombinant Full Length Rabbit Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-109) | |
Ovis aries (Sheep) | RFL-28356OF | Recombinant Full Length Sheep Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-271) | |
Procavia capensis habessinica (Abyssinian hyrax) | RFL-18498PF | Recombinant Full Length Procavia Capensis Habessinica Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-109) | |
Rattus norvegicus (Rat) | RFL-16839RF | Recombinant Full Length Rat Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-271) | |
Rhesus Macaque | AQP2-372R | Recombinant Rhesus monkey AQP2 Protein, His-tagged | Mammalian Cell | His | ||
Rhesus Macaque | AQP2-201R-B | Recombinant Rhesus Macaque AQP2 Protein Pre-coupled Magnetic Beads | HEK293 | |||
Rhesus Macaque | AQP2-201R | Recombinant Rhesus Macaque AQP2 Protein, His (Fc)-Avi-tagged | HEK293 | His (Fc)-Avi | ||
Talpa europaea (European mole) | RFL-6948TF | Recombinant Full Length Talpa Europaea Aquaporin-2(Aqp2) Protein, His-Tagged | E.coli expression system | His | Full Length (1-109) | |
Chicken | AQP2-5516C | Recombinant Chicken AQP2 | Mammalian Cell | His |
- Involved Pathway
- Protein Function
- Interacting Protein
- Aqp2 Related Articles
Aqp2 involved in several pathways and played different roles in them. We selected most pathways Aqp2 participated on our site, such as , which may be useful for your reference. Also, other proteins which involved in the same pathway with Aqp2 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
Pathway Name | Pathway Related Protein |
---|
Aqp2 has several biochemical functions, for example, glycerol channel activity, glycerol transmembrane transporter activity, water channel activity. Some of the functions are cooperated with other proteins, some of the functions could acted by Aqp2 itself. We selected most functions Aqp2 had, and list some proteins which have the same functions with Aqp2. You can find most of the proteins on our site.
Function | Related Protein |
---|---|
glycerol channel activity | AQP8A.1;AQP1A.1;AQP8B;AQP8;AQP5;AQP2;MIP;AQP10A;AQP3B |
glycerol transmembrane transporter activity | AQP3B;AQP3A;AQP9A;AQP10B;AQP2;AQP1;AQP10A;AQP9B |
water channel activity | MIP;AQP4;AQP6;AQP1;AQP9;AQP10A;AQP8A.1;AQP3A;AQP8 |
water transmembrane transporter activity | AQP4;AQP2;AQP10B;MIPA;AQP10A;AQP9A;AQP9;AQP9B;AQP8B |
Aqp2 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with Aqp2 here. Most of them are supplied by our site. Hope this information will be useful for your research of Aqp2.
- Q&As
- Reviews
Q&As (26)
Ask a questionYes, AQP2-related disorders can be inherited. Some forms of nephrogenic diabetes insipidus (NDI) are caused by genetic mutations in the AQP2 gene, which can be inherited from one or both parents. These genetic mutations result in impaired or absent functional AQP2 channels, leading to the development of NDI.
Yes, AQP2-related disorders can be inherited. Some forms of nephrogenic diabetes insipidus (NDI) are caused by genetic mutations in the AQP2 gene, which can be inherited from one or both parents. These genetic mutations result in impaired or absent functional AQP2 channels, leading to the development of NDI.
Yes, AQP2-related disorders can affect individuals of any age. Some forms of AQP2 dysfunction, like congenital nephrogenic diabetes insipidus (NDI), may be present from birth and can affect infants and young children. On the other hand, acquired forms of NDI can develop later in life due to factors such as medication side effects, genetic mutations, kidney damage, or other medical conditions. It is important to consider the potential presence of AQP2-related disorders in individuals of all ages who present with symptoms such as excessive thirst, frequent urination, and electrolyte imbalances.
Yes, AQP2-related disorders can affect individuals of any age. Some forms of AQP2 dysfunction, like congenital nephrogenic diabetes insipidus (NDI), may be present from birth and can affect infants and young children. On the other hand, acquired forms of NDI can develop later in life due to factors such as medication side effects, genetic mutations, kidney damage, or other medical conditions. It is important to consider the potential presence of AQP2-related disorders in individuals of all ages who present with symptoms such as excessive thirst, frequent urination, and electrolyte imbalances.
Yes, AQP2 undergoes several post-translational modifications, including phosphorylation and ubiquitination. Phosphorylation plays a critical role in the intracellular trafficking and translocation of AQP2 to the cell membrane, while ubiquitination is involved in the degradation of AQP2.
Yes, lifestyle modifications can be helpful in managing AQP2-related disorders, especially in conditions like nephrogenic diabetes insipidus (NDI). These modifications may include ensuring adequate fluid intake to prevent dehydration, dietary adjustments to maintain electrolyte balance, and avoiding excessive alcohol and caffeine consumption, which can increase urine production. It is always important to consult with a healthcare professional for personalized recommendations based on the specific condition and individual needs.
Yes, lifestyle modifications can be helpful in managing AQP2-related disorders, especially in conditions like nephrogenic diabetes insipidus (NDI). These modifications may include ensuring adequate fluid intake to prevent dehydration, dietary adjustments to maintain electrolyte balance, and avoiding excessive alcohol and caffeine consumption, which can increase urine production. It is always important to consult with a healthcare professional for personalized recommendations based on the specific condition and individual needs.
AQP2 dysfunction can result in an imbalance of electrolytes such as sodium and potassium. In conditions like nephrogenic diabetes insipidus (NDI), where AQP2 is impaired, there is impaired water reabsorption and excessive urinary output. This can lead to dehydration and subsequent electrolyte imbalances, including hyponatremia (low sodium levels) and hyperkalemia (high potassium levels).
AQP2 dysfunction can result in an imbalance of electrolytes such as sodium and potassium. In conditions like nephrogenic diabetes insipidus (NDI), where AQP2 is impaired, there is impaired water reabsorption and excessive urinary output. This can lead to dehydration and subsequent electrolyte imbalances, including hyponatremia (low sodium levels) and hyperkalemia (high potassium levels).
The potential complications and long-term effects of AQP2-related disorders can vary depending on the specific condition and its severity. In conditions like nephrogenic diabetes insipidus (NDI), if left untreated or poorly managed, there is an increased risk of dehydration, electrolyte imbalances, and kidney damage. These complications can lead to symptoms such as fatigue, muscle weakness, dizziness, and in severe cases, kidney failure. It is important for individuals with AQP2-related disorders to receive proper medical care and ongoing management to prevent and address these potential complications.
The potential complications and long-term effects of AQP2-related disorders can vary depending on the specific condition and its severity. In conditions like nephrogenic diabetes insipidus (NDI), if left untreated or poorly managed, there is an increased risk of dehydration, electrolyte imbalances, and kidney damage. These complications can lead to symptoms such as fatigue, muscle weakness, dizziness, and in severe cases, kidney failure. It is important for individuals with AQP2-related disorders to receive proper medical care and ongoing management to prevent and address these potential complications.
AQP2 plays a vital role in the urine concentrating mechanism in the kidneys. When vasopressin is released, AQP2 translocates from intracellular vesicles to the apical membrane of collecting duct cells. This process increases the permeability of water, allowing it to be reabsorbed from the urine back into the bloodstream, concentrating the urine.
AQP2 plays a vital role in the urine concentrating mechanism in the kidneys. When vasopressin is released, AQP2 translocates from intracellular vesicles to the apical membrane of collecting duct cells. This process increases the permeability of water, allowing it to be reabsorbed from the urine back into the bloodstream, concentrating the urine.
Mutations or dysregulation of AQP2 can lead to several disorders related to water balance, including nephrogenic diabetes insipidus (NDI). This condition impairs the kidney's ability to concentrate urine, resulting in excessive thirst and urination.
Yes, research on AQP2-related disorders is ongoing. Scientists are studying various aspects such as the molecular mechanisms behind AQP2 regulation, the development of targeted therapies for AQP2 dysfunction, and the identification of genetic mutations associated with these disorders. Furthermore, advancements in genetic testing techniques have allowed for better diagnosis and classification of AQP2-related disorders, leading to improved patient management and personalized treatment approaches.
Yes, research on AQP2-related disorders is ongoing. Scientists are studying various aspects such as the molecular mechanisms behind AQP2 regulation, the development of targeted therapies for AQP2 dysfunction, and the identification of genetic mutations associated with these disorders. Furthermore, advancements in genetic testing techniques have allowed for better diagnosis and classification of AQP2-related disorders, leading to improved patient management and personalized treatment approaches.
Yes, mutations in the AQP2 gene can cause hereditary nephrogenic diabetes insipidus (NDI), a condition characterized by the inability of the kidneys to concentrate urine. These mutations can affect AQP2 synthesis, trafficking, or function, leading to decreased water reabsorption and excessive urination.
Currently, there is no known cure for AQP2-related disorders. However, effective management and treatment approaches can significantly improve the quality of life for individuals with these conditions. Depending on the specific disorder, treatments may include medication, dietary modifications, fluid management, and addressing any underlying causes or contributing factors. Ongoing research aims to develop more targeted therapies and interventions to better manage and potentially reverse AQP2 dysfunction, but as of now, the focus is on symptom management and preventing complications.
Currently, there is no known cure for AQP2-related disorders. However, effective management and treatment approaches can significantly improve the quality of life for individuals with these conditions. Depending on the specific disorder, treatments may include medication, dietary modifications, fluid management, and addressing any underlying causes or contributing factors. Ongoing research aims to develop more targeted therapies and interventions to better manage and potentially reverse AQP2 dysfunction, but as of now, the focus is on symptom management and preventing complications.
Several physiological conditions can affect AQP2 expression. For example, dehydration stimulates the release of vasopressin, leading to increased AQP2 expression and water reabsorption. On the other hand, excessive water intake or the use of certain medications, such as diuretics, can suppress AQP2 expression, resulting in increased urine output.
Targeting AQP2 could potentially be useful in the treatment of certain water balance disorders. For instance, pharmacological agents that enhance AQP2 expression or function may be beneficial in patients with nephrogenic diabetes insipidus. However, further research is needed to develop specific and safe therapeutic strategies.
AQP2 is a specific member of the aquaporin family, characterized by its expression primarily in the kidney and involvement in water reabsorption. It differs from other aquaporin proteins in terms of its tissue distribution, regulation, and function.
The treatment options for AQP2-related disorders depend on the specific condition. In nephrogenic diabetes insipidus (NDI), medication options may include thiazide diuretics, which reduce urine production, or nonsteroidal anti-inflammatory drugs (NSAIDs) that can increase the responsiveness of the kidneys to vasopressin. In some cases, dietary adjustments and fluid management are also prescribed. However, the specific treatment plan will be determined by a healthcare professional and tailored to the individual patient's needs.
The treatment options for AQP2-related disorders depend on the specific condition. In nephrogenic diabetes insipidus (NDI), medication options may include thiazide diuretics, which reduce urine production, or nonsteroidal anti-inflammatory drugs (NSAIDs) that can increase the responsiveness of the kidneys to vasopressin. In some cases, dietary adjustments and fluid management are also prescribed. However, the specific treatment plan will be determined by a healthcare professional and tailored to the individual patient's needs.
Certain compounds, such as synthetic vasopressin analogs (vasopressin agonists) or vasopressin receptor antagonists, can modulate AQP2 expression or function indirectly by affecting the release or binding of vasopressin. These medications are used in the treatment of water balance disorders or conditions where AQP2 dysregulation is involved.
Vasopressin release is triggered by changes in blood osmolality or volume. When the osmolality increases or blood volume decreases, osmoreceptors or baroreceptors in the body signal the release of vasopressin. Vasopressin then binds to its receptor in the kidney, activating the intracellular cAMP signaling pathway. This pathway leads to phosphorylation of AQP2 and its subsequent translocation to the cell membrane, increasing water reabsorption.
Customer Reviews (5)
Write a reviewThis can be particularly important in clinical trials to ensure accurate and reliable results.
Their prompt assistance and guidance contribute to enhancing the success and efficiency of my work with the AQP2 protein.
Manufacturers may provide documentation of the protein's validation, which includes information about its purity, concentration, stability, and potential contaminants.
They can assist in identifying the most suitable experimental protocols or provide recommendations for optimal usage.
Manufacturers can provide researchers with purified and validated AQP2 protein, ensuring its quality and reliability for use in experiments and trials.
Ask a Question for All Aqp2 Products
Required fields are marked with *
My Review for All Aqp2 Products
Required fields are marked with *